Annovis Bio (FRA:07X) Research & Development: €31.77 Mil (TTM As of Mar. 2026)


FRA:07X Annovis Bio Inc FRA:07X
32 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Research & Development?

Annovis Bio FRA:07X -2.64% 32 Research & Development is €31.77 Mil as of Mar. 2026. GuruFocus rates FRA:07X with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Annovis Bio's Research & Development for the three months ended in Mar. 2026 was €14.46 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €31.77 Mil.

Annovis Bio  (FRA:07X) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Annovis Bio Research & Development Related Terms

Annovis Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Annovis Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio Research & Development Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 7.50 15.59 35.57 19.10 21.53

Annovis Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.64 4.48 5.36 7.47 14.46
FRA:07X
32GF Score
Annovis Bio Inc FRA:07X
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €31.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €31.77 Mil mean?
Annovis Bio (FRA:07X) has a Research & Development of €31.77 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Annovis Bio and its competitors.
Is Annovis Bio's Research & Development too high?
Annovis Bio's current Research & Development is €31.77 Mil. Overall, Annovis Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's Research & Development compare to CSBR and HYFT?
Annovis Bio's Research & Development of €31.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Annovis Bio and its competitors. Annovis Bio's current Research & Development is €31.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current Research & Development of €31.77 Mil. The current Research & Development is €31.77 Mil. Annovis Bio's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current Research & Development is €31.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
32GF Score

Get the complete analysis for FRA:07X

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price